Among small molecule drugs, such as small RNAs, oligonucleotides, peptides or vaccines, recombinant proteins are the most commonly. The discovery and development of protein therapeutics is growing rapidly because of their cell-specific modality and relative lack of compound-specific toxicity, and soon will equal and even surpass chemical entity drug development.